SchragLab

153 posts

SchragLab banner
SchragLab

SchragLab

@LabSchrag

We study shared molecular mechanisms between Alzheimer's disease and Cerebral Amyloid Angiopathy

Nashville, Tennessee Katılım Ağustos 2019
153 Takip Edilen264 Takipçiler
SchragLab retweetledi
Francis Deng, MD
Francis Deng, MD@francisdeng·
This #journalimage was AI-manipulated and retracted in NEJM. Can you spot the signs?
Francis Deng, MD tweet media
English
33
43
269
126.4K
SchragLab retweetledi
Shadi Yaghi
Shadi Yaghi@ShadiYaghi2·
ORIENTAL MEVO trial shows a benefit of EVT but the devil is in the details. The benefit was seen those with NIHSS 8 or more. Note that M3 occlusions did not benefit from EVT. #ISC26
Shadi Yaghi tweet media
English
2
22
85
4K
SchragLab retweetledi
Miriam Lense
Miriam Lense@miriamlense·
Wondering what’s been going on in the Music Cognition Lab? Check out our latest newsletter! Community engagement updates, research studies for all ages, and even an end of year matching gift opportunity! 🎵🎉 mailchi.mp/vumc/2025yeare…
English
0
3
6
346
SchragLab retweetledi
World Stroke Academy
World Stroke Academy@WorldStrokeEd·
#MondayTip 📊Pooled INTERACT data ✅Intensive BP lowering improves recovery in ICH ⏱️When started <3h (cutoff: 2.6h)➡️reduces haematoma growth ☝️Greatest benefit in mild–moderate ICH (ICH score) 🚨Early treatment improves outcomes👉supports CODE-ICH systems & future trial design
World Stroke Academy tweet media
English
2
39
103
7.5K
SchragLab retweetledi
Michael Okun
Michael Okun@MichaelOkun·
Today, the New England Journal of Medicine published what may be a landmark moment: doctors used customized gene editing inside a living baby to treat a deadly genetic disease called carbamoyl-phosphate synthetase 1 (CPS1) deficiency. Is it time to prepare for a world where we don’t just treat genetic diseases, we rewrite their story? Will gene editing change the future of medicine? Key Points for the Public: - Think of it as the first real-life genetic fire rescue; editing a baby’s DNA to prevent brain damage and death. - They used a tool called base editing, that is considered a precise cousin of CRISPR. - The authors corrected a disease-causing mutation in the liver using lipid nanoparticles. - You may recognize lipid nanoparticles as the same delivery technology used in mRNA COVID vaccines. - Their treatment was "tailor-made for a single patient." - The personalized gene-editing drug called k-abe was made in under 6 months (incredible!). - The single infant they used it on had a rare and fatal genetic disorder. - So far, the treatment has been safe and effective though followup has not been very long. - The infant tolerated more protein, required fewer medications, and recovered from infections without ammonia spikes (known to be bad for the brain). My take: This isn’t science fiction anymore, gene editing can be performed in real-time. Gene editing is moving beyond sickle cell. Lipid nanoparticle delivery facilitates re-dosing, making it safer and more flexible. What does this mean for the future? Neurogenetic diseases could be next in line? Could we start moving into rare brain conditions in children or even adult-onset disorders like Huntington’s or inherited forms of Parkinson’s? What was cool about this study was moving from diagnosis to therapy, in just months. The platforms like this one seem to be scalable. Many diseases could share delivery systems with only the guiding RNA changing. Ethics and oversight will be critical. Safety, long-term monitoring, and clear boundaries (e.g., no germline edits) must be built into the future of this therapy. Could this change the arc of progression for many diseases? We hope this technology and approach will move from lethal newborn disorders to slowly progressive neurologic conditions. Has gene editing moved past the dream stage? Is it time to prepare for a world where we don’t just treat genetic diseases, we rewrite their story? nejm.org/doi/full/10.10… #GeneEditing #CRISPR #Neurology #RareDisease #BaseEditing #PrecisionMedicine #NEJM #Parkinsons #Neurogenetics @ParkinsonDotOrg @FixelInstitute
Michael Okun tweet media
English
6
147
512
31K
SchragLab retweetledi
Jillian Berkman, MD
Jillian Berkman, MD@jillian_molli·
Another great @VUMCDiscoveries Stroke Symposium @schrag_matthew !!! Dr. Eliza Miller was an amazing speaker and I learned so much more about stroke in pregnancy ! Shoutout to my mentee on his awesome poster!
Jillian Berkman, MD tweet media
English
0
2
15
765
SchragLab retweetledi
Angela Jefferson
Angela Jefferson@AJtheScientist·
I am honored + humbled to have been elected as a 2024 Fellow of the American Association for the Advancement of Science. @AAAS Fellows are distinguished scientists, engineers, + innovators across the globe. It is a privilege be part of such an illustrious group.
AAAS@aaas

Congratulations to the new 2024 AAAS Fellows class! They are a distinguished cadre recognized for their achievements across disciplines, including research, and teaching. aaas.org/news/aaas-welc…

English
2
1
15
1K
SchragLab retweetledi
NANOS
NANOS@NANOSTweets·
Today at NANOS 2025, NANOS Board Member, Larry Frohman, MD presented the prestigious Thomas Carlow Distinguished Service Award to the incomparable (and legendary) Valerie Biousse, MD to a standing ovation. #nanos #nanos2025 #nanosconnect #nanosannualmeeting
NANOS tweet media
English
0
3
9
529
SchragLab retweetledi
Matthew Schrag
Matthew Schrag@schrag_matthew·
Come to this year’s Vanderbilt Stroke Symposium- live or virtual. Would be great to connect at this outstanding annual CME event.
English
0
1
4
689
SchragLab retweetledi
UCStrokeTeam
UCStrokeTeam@UCStrokeTeam·
It is with great pleasure that we anoint another chair from our division--please join us in congratulating *THE* Pooja Khatri on her new position as Chair of Neurology at Yale! Thank u for everything that u continue to do for us and for our patients!!! 🥳🥰
UCStrokeTeam tweet media
English
0
8
26
2.7K
SchragLab retweetledi
Stephan A Mayer
Stephan A Mayer@stephanamayer·
Does prior treatment with IV thrombolysis lead to improved outcome after stroke #thrombectomy? Yes! Says this big meta-analysis. The authors said “we did not establish non-inferiority” of prior lysis I think that means prior lysis is better 🤔 thelancet.com/journals/lance…
English
2
14
46
2.6K
SchragLab retweetledi
Michael Okun
Michael Okun@MichaelOkun·
Have you ever seen a case of autosomal dominant Alzheimer’s w/ ribbon like cortical calcifications? Wang and colleagues show us a case in @GreenJournal. Key Points: - The person had ‘recurrent headaches for 20 years, walking instability for 8 years, and memory loss and personality changes for 5 years.’ - 2 years ago, had postural tremors. - Mini-Mental State Examination = 18, Montreal Cognitive Assessment = 8 - Calcifications in the bilateral occipital cortex and also presence of symmetrical white matter hyperintensities on FLAIR imaging. -There was a c.A2059C (p.K687Q) heterozygous pathogenic variant in the APP gene. - The finding of ‘ribbon’ cortical calcifications on CT was the imaging characteristic the authors sought to share! neurology.org/doi/10.1212/WN… #alzheimer
Michael Okun tweet media
English
0
21
83
6.7K